Utilization of testing for mismatch repair deficiency was poor and underused in a large population of patients with colorectal cancer.
Levels of circulating tumor DNA predicted worse outcomes including relapse and survival in patients with resected stage II/III melanoma, according to the results of a study.
The addition of bevacizumab to lomustine for patients with progressive glioblastoma did not result in a significant improvement in overall survival.
Researchers are proposing the consideration of expanding criteria for liver debulking in pancreatic neuroendocrine tumors to include a threshold of greater than 70% debulking, intermediate grade tumors, positive margins, parenchyma-sparing resections, and extrahepatic metastases.
Even after 5 years of adjuvant endocrine therapy, women with ER-positive breast cancer experienced a steady rate of recurrences for as long as 20 years.
Treatment within 30 days of melanoma diagnosis was associated with improved outcomes; overall survival decreased in patients waiting longer than 90 days for surgery.
The majority of surveyed ovarian cancer patients required a 5-year survival benefit of 6% or less to justify an additional 50 miles of travel for cancer care.
Treatment with bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia compared with treatment with imatinib.
More than 25% of patients with recurrent, high-grade glioma treated with a gene therapy combination were alive more than 3 years after treatment, according to data from a subset of patients in a phase I clinical trial.
A large proportion of patients who underwent radical nephrectomy for kidney tumors were able to recover to their preoperative renal function, according to the results of a recent study.